• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    TSX Penny Stocks Spotlight InnoCan Pharma And Two Others

    Simply Wall St·07/10/2026 12:05:50
    Listen to the news

    As the Canadian market navigates a landscape of stable interest rates and easing inflationary pressures, investors are keenly observing opportunities that align with these economic conditions. Penny stocks, while often associated with speculative trading, can still offer intriguing prospects when backed by robust financials. In this article, we explore three such penny stocks that combine financial strength with potential for growth, highlighting their promise for investors seeking hidden value in smaller companies.

    Here's a peek at a few of the choices from the screener.

    InnoCan Pharma (CNSX:INNO)

    Simply Wall St Financial Health Rating: ★★★★★☆

    Overview: InnoCan Pharma Corporation is a pharmaceutical technology company operating in the United States, Canada, Europe, and internationally with a market cap of CA$15.75 million.

    Operations: The company generates revenue primarily through online sales, amounting to $25.27 million, with a minor contribution from other operations at $0.009 million.

    Market Cap: CA$15.75M

    InnoCan Pharma, with a market cap of CA$15.75 million, is a pre-revenue company focusing on innovative drug delivery systems. Recent earnings show sales of US$6.47 million for Q1 2026 but a net loss of US$0.972 million, highlighting ongoing financial challenges despite revenue generation primarily through online sales. The company's LPT-CBD product has garnered positive attention for its potential to enhance CBD bioavailability and patient adherence compared to conventional methods. While the firm faces high share price volatility and remains unprofitable, it benefits from experienced management and sufficient cash runway exceeding three years if growth continues at historical rates.

    CNSX:INNO Revenue & Expenses Breakdown as at Jul 2026
    CNSX:INNO Revenue & Expenses Breakdown as at Jul 2026

    Maxim Power (TSX:MXG)

    Simply Wall St Financial Health Rating: ★★★★★★

    Overview: Maxim Power Corp. is an independent power producer that develops, owns, and operates power and related projects in Canada, with a market cap of CA$270.08 million.

    Operations: The company's revenue is primarily derived from its power generation facilities, totaling CA$82.24 million.

    Market Cap: CA$270.08M

    Maxim Power Corp., with a market cap of CA$270.08 million, reported Q1 2026 revenue of CA$21.91 million and experienced a net loss of CA$0.194 million, reflecting challenges in profit growth amid declining earnings over the past five years. Despite this, the company benefits from being debt-free and having stable weekly volatility at 3%. Its seasoned board and management team contribute to operational stability, while its price-to-earnings ratio (20.8x) suggests relative value within the Renewable Energy sector. However, recent financials were impacted by a significant one-off gain of CA$8.9 million, affecting earnings quality assessments.

    TSX:MXG Revenue & Expenses Breakdown as at Jul 2026
    TSX:MXG Revenue & Expenses Breakdown as at Jul 2026

    Kenorland Minerals (TSXV:KLD)

    Simply Wall St Financial Health Rating: ★★★★★★

    Overview: Kenorland Minerals Ltd. is involved in the acquisition and exploration of mineral properties across North America, with a market cap of CA$196.10 million.

    Operations: The company generates CA$3.51 million from the exploration of mineral properties.

    Market Cap: CA$196.1M

    Kenorland Minerals Ltd., with a market cap of CA$196.10 million, is focused on mineral exploration in North America and has recently completed significant drilling programs at its Western Wabigoon and South Uchi projects. Despite generating CA$3.51 million in revenue from exploration activities, the company remains unprofitable, with losses increasing by 35.8% annually over the past five years. Kenorland's management team is experienced, and it maintains a stable weekly volatility of 10%. The company holds sufficient short-term assets to cover liabilities and has no debt, but its cash runway is limited to approximately nine months without additional capital infusion.

    TSXV:KLD Financial Position Analysis as at Jul 2026
    TSXV:KLD Financial Position Analysis as at Jul 2026

    Taking Advantage

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.